Zentalis Pharmaceuticals opened lower at $1.87, compared with its previous close of $1.89. In the last trading session, the stock traded between $1.64 and $1.91. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Zentalis Pharmaceuticals is now worth
$ 2.13
Resulting in a loss of
$ 97.87 (97.87%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-0.22 (-11.43%)
Day High
$1.91
Day Low
$1.64
Day Open
$1.87
Prev Close
$1.89
Volume
15,03,963
1W Return
-4.07%
1M Return
-33.73%
3M Return
-59.35%
6M Return
-59.57%
1Y Return
19.57%
Market Cap ($ Mn)
165
PE Ratio
-
PB Ratio
1.89
PEG Ratio
-
ROE
-49.80%
ROCE
-43.58%
EPS (TTM)
$-0.29
1 Week
-4.07%
1 Month
-33.73%
3 Months
-59.35%
6 Months
-59.57%
9 Months
-31.11%
Wedbush upgrades Zentalis Pharmaceuticals to Outperform, sets $6 target
Wedbush upgraded Zentalis Pharmaceuticals from Neutral to Outperform. Price target raised from $5 to $6. Analyst Robert Driscoll made the rating change.
2 days agoZentalis Pharmaceuticals grants stock options to four new hires
Granted non-qualified stock options for 136,000 shares to four new employees. Exercise price set at $1.85 per share, matching the closing market price. Options vest over four years with a one-year cliff followed by monthly vesting. Grants issued under the 2022 Employment Inducement Incentive Award Plan.
10 days agoHC Wainwright reiterates Buy rating on Zentalis with $10 target
HC Wainwright & Co. reiterated a Buy rating on Zentalis Pharmaceuticals. Price target maintained at $10 per share. Analyst Andres Y. Maldonado issued the update.
24 days agoZentalis reports 15.8-month median survival for azenosertib in ovarian cancer
Median overall survival reached 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients. Cyclin E1-negative subgroup showed a median overall survival of 7.5 months. Data derived from interim analysis of DENALI Part 1b study with September 2, 2025 cutoff. No new safety signals observed in the evaluated patient cohorts. Results support ongoing Phase 3 ASPENOVA trial for full approval in biomarker-selected population.
25 days agoWilliam Blair initiates Zentalis with Outperform on azenosertib potential
William Blair initiates Zentalis with Outperform rating, citing azenosertib potential. Firm projects peak worldwide sales of $1.3 billion for the oral WEE1 inhibitor. DENALI Part 2 results expected in first half of 2027 could support accelerated approval. Company holds $174.6 million in cash with runway extending into first half of 2028. Competition rising from Incyte and antibody-drug conjugates in ovarian cancer market.
1mo agoZentalis Pharmaceuticals to present at Wells Fargo, Morgan Stanley conferences
Zentalis Pharmaceuticals (NASDAQ: ZNTL) will hold a fireside chat at the Wells Fargo Healthcare Conference on September 8, 2026. Management is scheduled to present at the Morgan Stanley Global Healthcare Conference on September 14, 2026. Live webcasts and archived recordings of both events will be available on the company's investor relations website. The firm continues advancing azenosertib, a first-in-class WEE1 inhibitor for ovarian cancer treatment.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Zentalis Pharmaceuticals is now worth
$ 2.13
Resulting in a loss of
$ 97.87 (97.87%)
Note: Past profits do not guarantee future returns.
